Axogen(NASDAQ) AXGN

Axogen, Inc. helps surgeons repair damaged nerves throughout the body. Its products restore feeling and movement for injured patients. These tools reduce the need for extra surgeries on the patient.

Tools for Nerve Repair

• Avance Nerve Graft: Processed human nerve tissue used to bridge gaps in severed nerves without needing a second surgical site.
• Axoguard Nerve Connector: Pig-derived matrix that helps surgeons reconnect severed nerves without tension at the repair site.
• Axoguard Nerve Protector: Protective wrap made from pig tissue that shields damaged nerves during healing and prevents tissue attachments.
• Axoguard Nerve Cap: Tissue-based barrier that covers nerve ends to reduce the development of painful growths called neuromas.
• Avive+ Soft Tissue Matrix: Layered membrane used as an absorbable covering to separate tissues within the surgical area during healing.

Building for the Future

• Received FDA approval for the Avance Biologics License Application on Dec. 3, 2025.
• Acquired a minority stake and limited right of first refusal in Trace Biosciences to support nerve-imaging technology.
• Invested $7 million in Trace Biosciences on July 28, 2026, using cash on hand.
• Initiated the Nerve-RESTORE clinical study to compare product performance against traditional surgical nerve grafts.

Clinical Focus and Reach

Axogen focuses on accounts with high concentrations of microsurgeons, specifically targeting Level 1 trauma centers and academic-affiliated hospitals. Although the company distributes products in several international markets, it generates nearly all revenue from customers within the United States.

Measuring the Results

• Revenues were $69.7 million for the quarter ended June 30, 2026, up 23.1% year over year.
• Gross profit was $50.7 million for the quarter ended June 30, 2026, up 20.6% year over year.
• Net loss was $21.1 million for the six months ended June 30, 2026.
• Cash, cash equivalents, and investments totaled $111.4 million as of June 30, 2026.

Bottom Line

Axogen has transitioned from a medical device startup to a provider of specialized nerve repair solutions with FDA-approved biologics. Its focus on clinical evidence and surgeon adoption in trauma centers supports its growth in the peripheral nerve repair market.